Announcements Trials
Browse Landscape

Phase

Phase 1 5Phase 2 4Phase 1/2 3Phase 3 2

Status

Completed 3Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 4NETWORK 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1Genitourinary 1

Conditions

Stomach Neoplasms 2Urinary Bladder Neoplasms 1Squamous-Cell Non-Small-Cell Lung Cancer 1Gastrointestinal Neoplasms 1GastroEsophageal Cancer 1Gastric or Gastroesophageal Cancer 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 624pembrolizumab 500Paclitaxel 456Gemcitabine 438Carboplatin 435Cisplatin 418Radiotherapy 380fludarabine 365Nivolumab 340Docetaxel 277Bevacizumab 276Irinotecan 257Magnetic Resonance Spectroscopy 242Fluorouracil 228Dexamethasone 225Specimen Handling 221Capecitabine 218Rituximab 205Cytarabine 201Oxaliplatin 200Ipilimumab 199Temozolomide 197Biopsy 196fludarabine phosphate 194Etoposide 181Lenalidomide 176Doxorubicin 175Leucovorin 173Cetuximab 171Injections 170

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1 × Interventional × bemarituzumab × Clear all
NCT06978062 2025-06-05

NeoBEMA

European Organisation for Research and Treatment of Cancer - EORTC

Phase 1 Not yet recruiting
27 enrolled
Gastrointestinal

GastroEsophageal Cancer

NCT05267470 2025-03-25

FORTITUDE-201

Amgen

Phase 1 Terminated
74 enrolled 22 charts
Thoracic

Squamous-Cell Non-Small-Cell Lung Cancer

NCT02318329 2024-06-04

Open-Label, Dose-Finding Study Evaluating Safety and PK of FPA144 in Patients With Advanced Solid Tumors

Five Prime Therapeutics, Inc.

Phase 1 Completed
79 enrolled 21 charts
GastrointestinalGenitourinary

Urinary Bladder Neoplasms, Esophageal Neoplasms, Stomach Neoplasms

NCT03343301 2024-02-28

FIGHT

Five Prime Therapeutics, Inc.

Phase 1 Completed
12 enrolled 17 charts
Gastrointestinal

Gastrointestinal Neoplasms, Stomach Neoplasms

NCT05913115 2023-06-22

A Study Evaluating Safety and Pharmacokinetics of FPA144 in Japanese Patients With Advanced Gastric or Gastroesophageal Cancer

Amgen

Phase 1 Completed
6 enrolled
Gastrointestinal

Gastric or Gastroesophageal Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡